Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Atossa Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.819 Good morning, everybody. Thank you for joining us this morning for 24 00:00:05.819 -- 00:00:10.926 financial results. I'm with Jacques François, the group CFO. 00:00:10.926 -- 00:00:16.210 So on page three, of course, you have the normal, I would say, disclaimer. 00:00:16.453 -- 00:00:21.620 There is nothing new on this one. So on page four on the agenda, today 00:00:21.620 -- 00:00:26.887 I will share with you some key messages. Then I will go on the business highlights. 00:00:26.887 -- 00:00:31.923 On 2024, Jacques François then will take the lead for the 24 financial 00:00:31.923 -- 00:00:35.248 results. And then I will come back with key takeaways. 00:00:35.248 -- 00:00:38.973 And of course, we're going to take some Q&A after that. 00:00:38.973 -- 00:00:44.838 So with the allies first, so let's start on the 00:00:45.141 -- 00:00:47.141 page, 00:00:47.224 -- 00:00:50.366 which is number six. 00:00:50.969 -- 00:00:56.296 So I would say first on Q4, I think the good news 00:00:56.296 -- 00:01:00.729 is the I would say, commercial activity on Q4. 00:01:00.729 -- 00:01:05.755 As you can see, the Q4 book-to-bill, in fact, is very strong, 00:01:05.755 -- 00:01:07.357 above 110%, 00:01:07.357 -- 00:01:10.778 and stronger, in fact, than Q4 2023. 00:01:10.781 -- 00:01:14.986 We signed, in fact, a lot of multi-year contracts. 00:01:14.986 -- 00:01:20.070 It's both renewals in terms of contracts and wins. 00:01:20.192 -- 00:01:23.225 In the second point, 00:01:23.225 -- 00:01:28.692 We have a 2024 revenue organic evolution 00:01:28.692 -- 00:01:31.996 operating margin and free cash flow is roughly in line with the outlook that we have 00:01:31.996 -- 00:01:38.384 communicated in October, which I think is very important in terms of, I would...